华芢生物-B(02396)今日盘中大跌5.04%，延续了其上市首日的颓势。
消息面上，华芢生物昨日在港交所上市，发行价为38.2港元，但开盘即破发，收盘价较发行价大跌29.32%，显示市场对其前景持谨慎态度。公司目前暂无收入，且一直处于亏损状态，2025年前9个月亏损达1.34亿元，财务状况堪忧。
华芢生物是一家创新型生物制药公司，专注于伤口愈合的蛋白质药物开发，但其核心产品尚处于临床试验阶段，商业化前景不明。投资者对其长期盈利能力的担忧可能是导致股价持续下跌的主要原因。
华芢生物-B(02396)今日盘中大跌5.04%，延续了其上市首日的颓势。
消息面上，华芢生物昨日在港交所上市，发行价为38.2港元，但开盘即破发，收盘价较发行价大跌29.32%，显示市场对其前景持谨慎态度。公司目前暂无收入，且一直处于亏损状态，2025年前9个月亏损达1.34亿元，财务状况堪忧。
华芢生物是一家创新型生物制药公司，专注于伤口愈合的蛋白质药物开发，但其核心产品尚处于临床试验阶段，商业化前景不明。投资者对其长期盈利能力的担忧可能是导致股价持续下跌的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.